Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
A continuing challenge to determining the response to treatment of early syphilis (primary,
secondary, early latent syphilis) is exemplified by the substantial proportion of patients
who fail to achieve serological cure and remain serofast. Although retreatment is often done
in clinical practice, optimal management remains uncertain due to the paucity of data
regarding serological response to retreatment and long-term outcomes. Furthermore, the
investigators cannot rule out that the gradually increasing seroreversion/serological cure
rates may have been due to the natural decline in rapid plasma regain (RPR) titers after
initial therapy, rather than due to the additional dose of benzathine penicillin. Thus, the
investigators would like to conduct a clinical trial to compare the serological response
rates of serofast early syphilis cases retreated with three doses benzathine penicillin and
absence of any retreatment (control group).
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Penicillin G Penicillin G Benzathine Penicillin G Procaine Penicillins